Tyra Biosciences, Inc. TYRA Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $84.96M-15.7% | $77.39M-15.9% | $61.95M-40.4% | $98.49M-1.0% | $100.72M-60.4% | ||
| $884K-11.6% | $1M0.0% | $1M0.0% | $1M0.0% | $1M0.0% | ||
| $11.15M+98.2% | $9.45M+56.9% | $6.29M+14.8% | $5.88M+23.1% | $5.62M-32.4% | ||
| $394.61M+21.6% | $265.45M-23.6% | $281.22M-23.1% | $302.16M-20.2% | $324.57M-16.9% | ||
| $1.22M-20.2% | $1.31M-20.4% | $1.35M-24.8% | $1.41M-25.6% | $1.52M-4.5% | ||
| $9.89M-5.3% | $9.27M+25.7% | $12.59M+110% | $11.11M+137% | $10.44M+111% | ||
| $412.04M+20.0% | $282.61M-22.3% | $301.85M-20.7% | $321.5M-18.1% | $343.48M-15.1% | ||
| $3.64M+45.7% | $1.18M+99.7% | $1.99M+70.9% | $2.25M+42.4% | $2.5M-13.2% | ||
| $15.13M+33.6% | $16.44M+21.0% | $13.43M+24.3% | $11.08M+31.6% | $11.32M+107% | ||
| $488K+14.6% | $472K+14.6% | $456K+14.6% | $441K+15.1% | $426K+15.1% | ||
| $19.26M+35.2% | $18.09M+24.0% | $15.88M+28.3% | $13.77M+32.6% | $14.25M+63.4% | ||
| $5.21M-8.5% | $5.34M-8.1% | $5.46M-7.7% | $5.58M-7.2% | $5.7M-6.9% | ||
| $5.7M-6.9% | $5.81M-6.6% | $5.92M-6.3% | $6.02M-5.9% | $6.12M-5.6% | ||
| $24.47M+22.7% | $23.43M+14.8% | $21.34M+16.6% | $19.35M+17.9% | $19.94M+34.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $798.03M+32.5% | $630.04M+6.1% | $617.49M+5.3% | $609.26M+5.4% | $602.3M+5.1% | ||
| -$410.56M-46.9% | -$371.26M-47.7% | -$337.42M-49.5% | -$307.56M-52.5% | -$279.46M-52.7% | ||
| $107K-84.4% | $393K-49.0% | $442K-74.8% | $436K+337% | $688K+11,567% | ||
| $387.58M+19.8% | $259.18M-24.5% | $280.51M-22.6% | $302.15M-19.7% | $323.53M-17.0% | ||
| $412.04M+20.0% | $282.61M-22.3% | $301.85M-20.7% | $321.5M-18.1% | $343.48M-15.1% | ||
| $9.89M-5.3% | $9.27M+25.7% | $12.59M+110% | $11.11M+137% | $10.44M+111% | ||
| $9.89M-5.3% | $9.27M+25.7% | $12.59M+110% | $11.11M+137% | $10.44M+111% | ||
| $5.44M-8.5% | $5.57M-8.2% | $5.7M-7.9% | $5.82M-7.5% | $5.95M-7.3% | ||
| $9.89M-5.3% | $9.27M+25.7% | $12.59M+110% | $11.11M+137% | $10.44M+111% | ||
| $5.7M-6.9% | $5.81M-6.6% | $5.92M-6.3% | $6.02M-5.9% | $6.12M-5.6% | ||
| $798.03M+32.5% | $630.04M+6.1% | $617.49M+5.3% | $609.26M+5.4% | $602.3M+5.1% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $15.13M+33.6% | $16.44M+21.0% | $13.43M+24.3% | $11.08M+31.6% | $11.32M+107% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Tyra Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 20.49 — current assets exceed current liabilities.
- Where does Tyra Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Tyra Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.